clinical trial · NCT07288333
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
SchizophreniaNBI-1117570Placebo
brief summary
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
started
Feb 16, 2026
primary completion
Aug 1, 2027
completion
Aug 1, 2027
last updated
Apr 15, 2026
official title
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol